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Rad51 plays a crucial role in homologous recombination and recombinational DNA repair. Its activ-
ity is regulated by phosphorylation by the c-Abl kinase. Either Tyr54 or Tyr315 have been reported as
the target of phosphorylation but the interconnection between their phosphorylation is not known.
We prepared two speciﬁc antibodies that selectively detected the Tyr54 or Tyr315 phosphorylation
site of Rad51. By co-transfection of HeLa cells with c-Abl and Rad51, we clearly showed that both
Tyr54 and Tyr315 of Rad51 are phosphorylated by c-Abl. Furthermore, we showed that the phos-
phorylation of Tyr315 stimulates that of Tyr54, which indicates that the phosphorylation of Rad51
by the c-Abl kinase is a sequential process.
Structured summary:
MINT-7034009: cABL (uniprotkb:P00519) physically interacts (MI:0218) with RAD51 (uniprotkb:Q06609)
by pull down (MI:0096)
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction fected Rad51 activity by enhancing its association with Rad52Rad51protein is involved inhomologous recombination (HR)and
repair of DNAdouble-strand breaks (DSBs) produced by exposure to
ionizing radiation [1,2]. Rad51activity is basedonpairingand strand
exchange between homologous DNAs. In response to radiation-in-
duced DNA damage, Rad51 forms distinct subnuclear complexes
called foci [3–7]. Although the molecular regulation of Rad51 levels
and activity has not yet been completely deﬁned, the Abl family of
tyrosine kinases appears to play a signiﬁcant role [8–10].
c-Abl is a tyrosine kinase involved in DNA repair signal trans-
duction [11–14]. Several studies have shown that c-Abl interacts
with and phosphorylates Rad51 on tyrosine in response to DNA
damage in an ATM-dependent manner [15]. In spite of the impor-
tance of Rad51 phosphorylation in recombinase activity, the inter-
connection between the phosphorylation site(s) is (are) not clearly
determined. In one previous study, the authors described a single
phosphorylation of Rad51 on the Tyr54 residue [16] while other
authors provided evidence of Tyr315 phosphorylation by c-Abl,
which negatively affected Rad51–DNA binding or positively af-chemical Societies. Published by E
SA, bovine serum albumin;
yrosine 54 or 315
.[17]. It remains unclear whether c-Abl can phosphorylate a single
or both tyrosines in a simultaneous or in a sequential manner.
Immunoblot analysis is commonly used for protein analysis but
the study of protein post-translational modiﬁcations by this tech-
nique is largely limited by antibody speciﬁcity and the sensitivity
of detection. To overcome these difﬁculties,we prepared highly spe-
ciﬁc anti-phospho-Y54 and anti-phospho-Y315 antibodies. Using
these and secondary antibodies coupled to ﬂuorophores, we ob-
tained a strong tool for the detection of Rad51phosphorylation sites.
We provide evidence that c-Abl can phosphorylate both Tyr54 and
Tyr315 residues of Rad51 in a sequential manner, Tyr315 ﬁrst fol-
lowedbyTyr54. SH2domain of c-Abl recognizes thephosphorylated
Tyr315 site which is required for Tyr54 phosphorylation. We also
propose an explanation of the apparent discrepancies in the results
on which tyrosine residues in Rad51 are phosphorylated by c-Abl.2. Materials and methods
2.1. Generation of phosphospeciﬁc antibodies by afﬁnity
chromatography
Two peptides containing Rad51 tyrosine phosphorylation sites
Tyr54 and Tyr315, respectively, were designed, synthesized,lsevier B.V. All rights reserved.
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(Fig. 1). Sera were applied to a Sulfolink (Pierce) afﬁnity column
coupled to the immunizing phosphopeptide. Retained antibodies
were eluted and applied to an afﬁnity column coupled to the cor-
responding non-phosphopeptide and the antibodies of interest
were collected in the ﬂow-through. Anti-phospho-Y54
(anti-pY54) antibodies were thus puriﬁed by two sequential
immune-afﬁnity columns coupled to either the phospho- or the
non-phosphopeptide. The puriﬁcation of the anti-phospho-Y315
(anti-pY315) antibodies required one additional step using an
afﬁnity column conjugated to the Y54 phosphopeptide. After each
puriﬁcation step, the antibody speciﬁcity was evaluated by peptide
microarrays containing increasing concentrations of phosphopep-
tides (pY54, pY301 and pY315) or non-phosphopeptides (Y54,
Y301 and Y315). Bovine serum albumin (BSA) and phospho-
tyrosineBSA (phosphoBSA) were added to the microarray as a
protein control.
2.2. Plasmid construction
Flag-tagged wild-type or kinase-dead (KD) c-Abl, or HA-tagged
Rad51 eukaryotic expression vectors, driven by a human elonga-
tion factor-1 promoter (the tag sequences were located upstream
of the coding sequences) have been described previously [18].
Tyr54, Tyr301 and Tyr315 of human Rad51 were mutated to phen-
ylalanine, using a PCR strategy.
2.3. Transfection and cell lyses
HeLa cells were a kind gift from Dr. Pitard (Nantes, France). Cells
were maintained in DMEM (Gibco) supplemented with 10% FBS
and 5% antibiotics in a humiﬁed atmosphere with 5% CO2. HeLa
cells were transiently transfected (FuGENE6 reagent) separately
or co-transfected with plasmids carrying wild-type or mutated
Rad51 and c-Abl. Twenty-four hours after transfection, cells were
washed with ice-cold PBS and lysed in cold EBC Buffer (50 mM Tris,
pH 7.6, 120 mM NaCl, 0.5% Nonidet P-40, 1 mM EDTA, 1 mM b-M A M Q M Q L E A N A D T S V E E E S 
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pY301 peptide: RLY(PO3H2)LRKGRGETRIC
Fig. 1. Rad51 and antigenic peptide sequences. Y54 and Y315 peptides used to generate
motifs recognized by c-Abl are indicated by a grey background. The sequence of the Y3mercaptoethanol, 50 mM NaF and 1 mM Na3VO4) plus a protease
inhibitor cocktail (Sigma) [17]. After incubation for 20 min on ice,
cells were scraped from plates, sonicated and centrifuged at
13 000 rpm for 10 min at 4 C. Protein concentration was deter-
mined by the Bradford method (Bio-Rad).
2.4. Immunoblot analyses
Equal amounts of cellular lysate proteins were separated by
electrophoresis on 10% SDS–polyacrylamide gels and transferred
to nitrocellulose membranes (Amersham). Membranes were
blocked for 1 h in 0.1% TBS-Tween20 containing 5% BSA or 2%
Amersham blocking agent. Primary antibodies were mouse anti-
Rad51, anti-c-Abl, anti-tubulin or rabbit anti-pY54, anti-pY315,
or anti-HA. Membranes were washed three times with 0.1% TBS-
Tween20 for 10 min and incubated for 1 h with anti-mouse
Alexa-Fluor700-conjugated or anti-rabbit Alexa-Fluor800-conju-
gated secondary antibodies (Molecular Probes). Membranes were
scanned at 700 nm and 800 nm, respectively, using the Odyssey
infrared imaging system (Li-cor, Biosciences). Images were treated
and proteins were quantiﬁed with the Odyssey software. Amounts
of Rad51 and phospho-Rad51 on the blot were normalized to the
amount of tubulin and the ratio of phospho-Rad51 to total Rad51
was determined from three independent experiments.
2.5. GST pull-down analysis
Cell lysates equivalent to 2  106 HeLa cells were incubated
with 100 ll of a 50% slurry of glutathione-agarose beads (GE
Healthcare) for 2 h at 4 C with end-over-end mixing. After
centrifugation, precleared lysates were transferred to a clean
microcentrifuge tube. Ten micrograms of GST-Abl SH2 domain
(Marligen) was added to each tube and the mixture was incubated
at 4 C for 2 h with end-over-end mixing. Beads were washed four
times with lysis buffer (20 mM Tris, pH 8, 200 mM NaCl, 0.5% Non-
idet P-40, 1 mM EDTA, 1 mM PMSF) as previously described in [19].
The beads were mixed and boiled directly into an equal volume ofF G P Q P I S R L E Q C G I N A N
P K K E L I N I K G I S E A K A D
eptide
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GIC
phosphospeciﬁc antibodies are underlined. The PXXP and phosphoYXXP sequence
01 peptide used as a negative control is also shown.
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SDS–PAGE gel and analyzed by Western blotting with anti-GST
(Sigma) and anti-pY315 antibodies.
3. Results
3.1. Validation of the phospho-speciﬁc antibodies
The sera obtained from rabbits immunized with a phospho-
Tyr54 or a phospho-Tyr315 peptide (see Fig. 1 for peptide se-
quences) contain different antibodies. Phospho-speciﬁc antibodies
were isolated through sequential phospho- and dephospho-afﬁnity
chromatography from crude sera (see Section 2).
Using peptide microarrays spotted with the immunizing and
the corresponding dephosphopeptides, we followed and estimated
the anti-pY54 and anti-pY315 antibody speciﬁcity after each step
of puriﬁcation (Fig. 2). pBSA which presents a large quantity of
phosphotyrosine per protein mole and thus enables the potential
cross-reactivity of antibodies to be detected and a pY301 phospho-
peptide was also spotted on the microarrays and used as negative
controls.
The anti-pY54 speciﬁc antibody was isolated by two afﬁnity
chromatography steps. After the ﬁrst step on a pY54-coupled afﬁn-
ity column, the eluted product was mainly speciﬁc to the pY54
peptide but it also recognized the non-phosphorylated Y54 peptide
(Fig. 2A). The eluted antibodies were then applied to a Y54-dephos-
phopeptide afﬁnity column. The pY54 speciﬁc antibodies do not
bind to this column and are collected in the ﬂow-through. Fig. 2A
clearly shows that the obtained antibodies are highly speciﬁc to
the pY54 site.
Unlike anti-pY54 antibody puriﬁcation, three afﬁnity chroma-
tography steps were required to isolate the anti-pY315 speciﬁc
antibodies. After the ﬁrst step of puriﬁcation on a pY315-coupled
column, the eluted antibodies recognized preferentially the
pY315 peptide but also the other phosphorylated peptides, as well
as pBSA and the Y315 peptide. These antibodies were then applied
to a Y315-dephosphopeptide afﬁnity column. This second step of
puriﬁcation eliminated the Y315 peptide cross-recognition, as
shown in Fig. 2B. A ﬁnal third step using a pY54 peptide conjugated
column was necessary to eliminate the phosphotyrosine-recogniz-
ing antibodies. Finally, the ﬂow-through containing the anti-pY315Fig. 2. Conﬁrmation of anti-phosphoY54 (anti-pY54) and anti-phosphoY315 (anti-pY315
of afﬁnity chromatography. Anti-pY54 (A) and anti-pY315 (B) antibody speciﬁcity was ev
phosphoBSA) or non-phosphopeptides (Y54, Y301, Y315 and BSA). The concentration ofantibodies presents high speciﬁcity to the pY315 peptide, as shown
in Fig. 2B. Fig. 2 shows that our antibodies recognize neither pBSA
nor the pY301 peptide which conﬁrms the high speciﬁcity of these
antibodies.
3.2. c-Abl kinase can phosphorylate Tyr54 and Tyr315 residues of
Rad51 in cells
Firstly, we transiently expressed wild-type or mutated HA-
tagged Rad51 in HeLa cells. In the mutated protein the tyrosine res-
idue at positions 54, 301 or 315 was replaced with a phenylalanine
(Rad51-Y54F, Rad51-Y301F and Rad51-Y315F mutants, respec-
tively). Cells were lysed and the expression level of exogenous
Rad51 was quantiﬁed by immunoblotting with anti-Rad51 and
anti-HA antibodies in order to ensure that the intracellular quan-
tity of transfected Rad51 was equivalent between the wild-type
and the mutated forms. Fig. 3 clearly shows that the expression
levels of the exogenous wild-type Rad51 and the exogenous mu-
tated Rad51 proteins are comparable. Transfection of wild-type
or mutated Rad51 protein is constant, equivalent and reproducible.
Secondly, we transiently co-expressed HA-tagged Rad51 and
Flag-tagged c-Abl in HeLa cells. An anti-c-Abl antibody was used
to conﬁrm the efﬁciency and reproducibility of c-Abl transfection.
The level of c-Abl protein expression was analyzed by immuno-
blotting of cellular extracts co-transfected with wild-type and mu-
tated Rad51. Fig. 3B shows that c-Abl expression is equivalent
when co-transfected with wild-type and mutated Rad51.
Fig. 3B also shows that the expression level of the exogenous
Rad51 protein is comparable between wild-type and mutated
Rad51 when co-transfected with c-Abl.
After conﬁrming the equal expression of exogenous proteins in
co-transfected cells, we analyzed the level of Rad51 phosphoryla-
tion by immunoblotting with our puriﬁed anti-pY315 and anti-
pY54 antibodies. The amount of total Rad51, as well as the amount
of Rad51 phosphorylated on Tyr54 and Tyr315 was quantiﬁed by
Western blot analysis in cell extracts co-expressing c-Abl and
wild-type or mutated Rad51 (Y54F or Y315F). Anti-Rad51, anti-
pY54 and anti-pY315 antibodies, respectively, were used. Another
Rad51 mutant, Y301F, was used as a negative control to conﬁrm
the speciﬁcity of antibodies. From these quantiﬁcations, the phos-
pho-Rad51/total Rad51 ratio was determined in order to estimate) antibody speciﬁcity by dot blotting. Antibodies were puriﬁed by two or three steps
aluated after each step of puriﬁcation by using phospho- (pY54, pY301, pY315 and
each peptide and of the BSA protein ranged from 3 pg to 6 ng.
Fig. 3. Rad51 and c-Abl expression in transfected HeLa cells. HeLa cells were transfected with Rad51 or co-transfected with c-Abl and Rad51 and lysed 24 h post-transfection.
Whole-cell extracts were resolved by SDS–10% PAGE and analyzed by Western blot. (A) Cells were transfected with wild-type (wt) or mutated Rad51 (Y54F, Y301F or Y315F).
(B) Co-transfected cell extracts were analyzed by Western blot using antibody, as indicated. (C and D) Cells were transfected or co-transfected with Rad51 wt, active c-Abl (c-
Abl wt) or dead-kinase c-Abl (c-Abl KD). Cell extracts were analyzed by Western blot using antibody, as indicated. The control lane corresponds to untransfected cell extract.
Tubulin was used as a loading control.
1870 M. Popova et al. / FEBS Letters 583 (2009) 1867–1872the level of phosphorylation on tyrosine 315 (bar graph of Fig. 4A)
and tyrosine 54 (bar graph of Fig. 4B).
Fig. 4A shows the phosphorylation of Tyr315 and indicates that
the level of this phosphorylation is similar between the wild-type
and the control Rad51-Y301F mutant. Moreover, the Tyr315F
mutation of Rad51 eliminates Y315 phosphorylation since no sig-
niﬁcant phosphorylation is observed. These results conﬁrmed the
intracellular phosphorylation of Rad51 on Tyr315 by c-Abl
(Fig. 4A).
The same analysis was carried out using the anti-pY54 anti-
body. Fig. 4B shows that Rad51wt is phosphorylated on Tyr54.
For the ﬁrst time, we provide direct evidence that c-Abl can phos-
phorylate Rad51 on Tyr54 in cells. A comparable level of Tyr54
phosphorylation is observed with the Rad51-Y301F control
mutant.
3.3. Interconnection between Y54 and Y315 phosphorylation by c-Abl
By using Rad51 mutants, we conﬁrmed that c-Abl can phos-
phorylate Rad51 at Tyr54 and Tyr315. No phosphorylation of
Rad51 was observed when inactive c-Abl was expressed, which
conﬁrms that Rad51 phosphorylation is induced by c-Abl (Fig. 3C
and D).
As shown in Fig. 4A, Tyr54 phosphorylation is absent when
Rad51 is mutated as Y54F, which conﬁrms the ability of c-Abl to
phosphorylate Rad51 on Tyr54 in cells.An unexpected result was obtained with Rad51-Y315F. This
mutation induced a signiﬁcant decrease in Tyr54 phosphorylation
with a Rad51pY54/Rad51 ratio of less than 20% compared to wild-
type Rad51 (Fig. 4B, lane Y315F). No effect on the level of Tyr54
phosphorylation was observed when Tyr301 was mutated to Phe.
These results show that Tyr54 phosphorylation is dependent on
Tyr315 phosphorylation.
A GST pull-down assay was performed to investigate the inter-
action between the SH2 domain of c-Abl and phospho-Rad51. The
results presented in Fig. 5 demonstrate a unique band revealed by
the anti-pY315 antibody which conﬁrms the interaction between
the SH2 domain of c-Abl and Rad51 phosphorylated on Tyr315.4. Discussion
In order to study the phosphorylation of Rad51 we prepared
speciﬁc anti-phospho-Rad51 antibodies. Tyrosine phosphorylation
is speciﬁc to multicellular organisms and plays a crucial role in sig-
nal transduction which is frequently related to cancer. Its detection
is difﬁcult since it constitutes less than 0.1% of total intracellular
protein phosphorylation [20]. Anti-phosphotyrosine antibodies
are commercially available but they cannot distinguish between
the different phosphorylation sites of the same protein. Moreover,
a large number of false positive interactions can be detected. Using
afﬁnity chromatography, we have obtained high afﬁnity antibodies
Fig. 4. Intracellular phosphorylation of Tyr54 is dependent on Rad51 Tyr315 phosphorylation. HeLa cells were transfected with Rad51 wt or co-transfected with c-Abl and
wild-type (wt) or mutated (Y54F, Y301F or Y315F) Rad51 and lysed after 24 h. Expression of phosphorylated Rad51 was detected in total cell lysates by Western analysis
using either anti-pY315 (A) or anti-pY54 (B) antibodies and was compared to total Rad51. The bar graphs indicate the ratio of Rad51 phosphorylated at Y315 (A) and at Y54
(B) to Rad51 from quantiﬁcation of the blotting data (expressed as a percentage compared to Rad51wt). Results represent the average and S.D. of three independent
experiments. Error bars indicate S.D.
Fig. 5. Interaction of SH2 domain of c-Abl kinase with phosphorylated Rad51. HeLa
cells were transfected or co-transfected with Rad51 wt and c-Abl wt and lysed after
24 h. Lysates were incubated with glutathione-beads and GST-SH2 peptide domain
for 2 h. The pull-down products were detected by Western blot with anti-pY315
followed by anti-GST antibody.
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immunoblotting approach allowed us to establish a high-perfor-
mance method for the detection of Rad51 phosphorylation sites.
In HeLa cells co-transfected with c-Abl and Rad51, we have
shown that Rad51 is phosphorylated on tyrosine 54 and tyrosine
315 by c-Abl. Indeed, the replacement of the tyrosine residue by
a phenylalanine residue decreases the level of Rad51 phosphoryla-
tion. Moreover, we found that the Y315F mutation eliminates both
Tyr54 and Tyr315 phosphorylation. There are two possible expla-
nations for the effect of the Y315F mutation on Tyr54 phosphory-
lation. This mutation could induce important structural
modiﬁcations in the Rad51 protein, which could inhibit the access
of c-Abl to Rad51. Another possibility is that the phosphorylation
of Tyr315 by c-Abl stimulates the phosphorylation of the Tyr54 site
by the same kinase.
The ﬁrst hypothesis seems unlikely. As reported by Takizawa
et al. [21], the substitution of tyrosine 315 by a phenylalanine does
not affect the structure or the function of Rad51. Indeed, the
Rad51-Y315F mutant exhibited DNA-binding and strand-exchange
activities similar to those of the wild-type protein (Y315F was usedas a positive control mutant). The Y315F mutation only affected
the ability of the substituted residue to be phosphorylated.
Furthermore, the second hypothesis is supported by the fact
that c-Abl fulﬁls its biological function through domain interac-
tions with other cellular components. Two binding domains, an
SH3 and an SH2 domain, which are located at the N terminus of
c-Abl, can bind peptides carrying PXXP and (p)YXXP motifs,
respectively [14,22]. There are two PXXP motifs (amino acids
283–286 and amino acids 318–321) and one potential (p)YXXP
motif (amino acids 315–318) in the Rad51 sequence (Fig. 1). The
phosphorylation of Tyr315 reveals one new (p)YXXP recognition
motif. Indeed we show for the ﬁrst time that c-Abl SH2 domain
recognizes and interacts selectively with the pY315 Rad51 form.
This c-Abl/phospho-Rad51 interaction could permit Tyr54 phos-
phorylation, explaining its dependence on the phosphorylation of
Tyr315.
The phosphorylation of Tyr315 was not observed by mass spec-
trometry analysis of Rad51 phosphorylation in vitro. Only the
phosphorylation of Tyr54 was detected [16].
In this assay the Rad51 protein was digested by trypsin into
smaller peptides. The absence of detection of Tyr315 phosphoryla-
tion could be explained by the length (28 amino acids) and nega-
tive charge (pHi 4.03) of the Tyr315-containing fragment which
could interfere with its detection by mass spectroscopy [20]. The
Tyr54-containing fragment is shorter (17 amino acids) and less
negatively charged (pHi 4.83) than the Tyr315-containing one.
These length and charge differences make it difﬁcult to obtain an
evaporated fragment containing Tyr315, which may explain the
apparent absence of Tyr315 phosphorylation by c-Abl of the
Rad51 protein. This also shows that our results are not contradic-
tory with those proposed by Yuan et al.
Successive phosphorylation of Y315 followed by Y54 is more
than likely. The biological signiﬁcance of this double phosphoryla-
tion of Rad51 remains unclear. It has been reported that the Tyr54-
containing N-terminal region of Rad51 directly interacts with DNA
[23,24], while the phosphorylation of Tyr315 which is located near
1872 M. Popova et al. / FEBS Letters 583 (2009) 1867–1872the subunit interface could affect polymerization of Rad51 [25].
This sequential phosphorylation may thus modulate Rad51 afﬁnity
for the damaged DNA.
Because our speciﬁc antibodies have been generated against
peptides, the recognition of their epitopes may be less efﬁcient in
native conditions such as in immunoprecipitation or immunoﬂuo-
rescence approaches. By contrast, our antibodies can be used in
immunoblotting conditions. Thus, they allowed us to differentially
detect the phosphorylation states of Rad51 and will help under-
stand the physiological role of each phosphorylation.Acknowledgements
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